An Open-label, Randomised Trial of Bortezomib Consolidation (With Thalidomide and Prednisolone) Vs Thalidomide and Prednisolone Alone in Previously Untreated Subjects With Multiple Myeloma After Receiving Bortezomib, Cyclophosphamide, Dexamethasone (VCD) Induction and Autologous Stem Cell Transplant.

Trial Profile

An Open-label, Randomised Trial of Bortezomib Consolidation (With Thalidomide and Prednisolone) Vs Thalidomide and Prednisolone Alone in Previously Untreated Subjects With Multiple Myeloma After Receiving Bortezomib, Cyclophosphamide, Dexamethasone (VCD) Induction and Autologous Stem Cell Transplant.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Bortezomib (Primary) ; Prednisolone; Thalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms VCAT
  • Sponsors Janssen; Janssen-Cilag
  • Most Recent Events

    • 15 May 2017 Planned End Date changed from 1 Jan 2018 to 28 Feb 2018.
    • 30 Sep 2016 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
    • 09 Mar 2016 Planned End Date changed from 1 Feb 2018 to 1 Dec 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top